Correspondence Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies

被引：15

作者：

Maglione, Alessandro ^{[1
]}

Morra, Marta ^{[1
]}

Meroni, Raffaella ^{[1
]}

Matta, Manuela ^{[1
]}

Clerico, Marinella ^{[1
]}

Rolla, Simona ^{[1
]}

机构：

[1] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 61卷

关键词：

Multiple sclerosis; Anti-SARS-Cov2; vaccine; Booster; Third dose;

D O I：

10.1016/j.msard.2022.103776

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of antireceptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and the booster in pwMS receiving ocrelizumab, fingolimod and cladribine. A significant increase of anti-RBD IgG seroconversion was observed after booster respect to the vaccination cycle. Results obtained from this study will be useful for the management of pwMS in relation to their disease modifying therapy (DMT) and for any future vaccination campaign.

引用

页数：3

共 50 条

[41] Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
Ciampi, Ethel
Uribe-San-Martin, Reinaldo
Soler, Bernardita
Garcia, Lorena
Guzman, Jorge
Pelayo, Carolina
Jurgensen, Lukas
Guzman, Ignacio
Vera, Francisco
Galleguillos, Lorna
Carcamo, Claudia
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
[42] Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma
Onishi, Akio
Matsumura-Kimoto, Yayoi
Mizutani, Shinsuke
Isa, Reiko
Fujino, Takahiro
Tsukamoto, Taku
Miyashita, Akihiro
Okumura, Keita
Nishiyama, Daichi
Hirakawa, Koichi
Shimura, Kazuho
Kaneko, Hiroto
Kiyota, Miki
Kawata, Eri
Takahashi, Ryoichi
Kobayashi, Tsutomu
Uchiyama, Hitoji
Uoshima, Nobuhiko
Nukui, Yoko
Shimura, Yuji
Inaba, Tohru
Kuroda, Junya
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (01) : 62 - 70
[43] Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
Capuano, Rocco
Bisecco, Alvino
Conte, Miriana
Donnarumma, Giovanna
Altieri, Manuela
Grimaldi, Elena
Franci, Gianluigi
Chianese, Annalisa
Galdiero, Massimiliano
Coppola, Nicola
Tedeschi, Gioacchino
Gallo, Antonio
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
[44] The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients
Saiag, Esther
Grupper, Ayelet
Avivi, Irit
Elkayam, Ori
Ram, Ron
Herishanu, Yair
Cohen, Yael
Perry, Chava
Furer, Victoria
Katchman, Helena
Rabinowich, Liane
Ben-Yehoyada, Merav
Halperin, Tami
Baruch, Roni
Goldshmidt, Hanoch
Hagin, David
Ben-Ami, Ronen
Sprecher, Eli
Bomze, David
CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (05) : 735.e5 - 735.e8
[45] Negative impact of immunoparesis in response to anti-SARS-CoV-2 mRNA vaccination of patients with multiple myeloma
Akio Onishi
Yayoi Matsumura-Kimoto
Shinsuke Mizutani
Reiko Isa
Takahiro Fujino
Taku Tsukamoto
Akihiro Miyashita
Keita Okumura
Daichi Nishiyama
Koichi Hirakawa
Kazuho Shimura
Hiroto Kaneko
Miki Kiyota
Eri Kawata
Ryoichi Takahashi
Tsutomu Kobayashi
Hitoji Uchiyama
Nobuhiko Uoshima
Yoko Nukui
Yuji Shimura
Tohru Inaba
Junya Kuroda
International Journal of Hematology, 2024, 119 : 50 - 61
[46] Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs
Capuano, Rocco
Prosperini, Luca
Altieri, Manuela
Lorefice, Lorena
Fantozzi, Roberta
Cavalla, Paola
Guaschino, Clara
Radaelli, Marta
Cordioli, Cinzia
Nociti, Viviana
Boffa, Laura
Ragonese, Paolo
Di Gregorio, Maria
Pinardi, Federica
Torri Clerici, Valentina
De Luca, Giovanna
Gajofatto, Alberto
Paolicelli, Damiano
Tortorella, Carla
Gasperini, Claudio
Solaro, Claudio
Cocco, Eleonora
Bisecco, Alvino
Gallo, Antonio
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : 856 - 865
[47] Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables
Barone, Stefania
Palmieri, Camillo
Gallelli, Luca
Rania, Vincenzo
Pascarella, Angelo
Abatino, Antonio
Bruno, Pietro Antonio
Casarella, Alessandro
Pasquale, Marilisa
Manzo, Lucia
De Sarro, Giovambattista
Gambardella, Antonio
Valentino, Paola
NEUROTHERAPEUTICS, 2024, 21 (02)
[48] Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern
Lasagna, A.
Bergami, F.
Lilleri, D.
Percivalle, E.
Quaccini, M.
Serra, F.
Comolli, G.
Sarasini, A.
Sammartino, J. C.
Ferrari, A.
Arena, F.
Secondino, S.
Cicognini, D.
Schiavo, R.
Lo Cascio, G.
Cavanna, L.
Baldanti, F.
Pedrazzoli, P.
Cassaniti, I
ESMO OPEN, 2022, 7 (05)
[49] Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
Habek, Mario
Brecl, Gregor Jakob
Kes, Vanja Basic
Rogic, Dunja
Barun, Barbara
Gabelic, Tereza
Emersic, Andreja
Ledinek, Alenka Horvat
Grbic, Nevena
Lapic, Ivana
Segulja, Dragana
Duric, Koraljka
Adamec, Ivan
Skoric, Magdalena Krbot
JOURNAL OF NEUROIMMUNOLOGY, 2021, 359
[50] Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies
Wallach, Asya I.
Schiebel, Matthew
Picone, Mary Ann
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 63

← 1 2 3 4 5 →